0639 Long-term Safety and Timing of Adverse Events with Low-Sodium Oxybate in a Phase 3 Idiopathic Hypersomnia Study
Sign Up to like & getrecommendations! Published in 2024 at "SLEEP"
DOI: 10.1093/sleep/zsae067.0639
Abstract: Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration for the treatment of idiopathic hypersomnia in adults. To examine the long-term safety of LXB in this population, this post hoc analysis… read more here.
Keywords: idiopathic hypersomnia; common teaes; oxybate; safety ... See more keywords